Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CARCINOSTATIC AGENT, CARCINOGENESIS INHIBITOR AND LIFE-PROLONGING AGENT, COMPRISING NOVEL COMPOUND WITH MTORC1 INHIBITORY EFFECT
Document Type and Number:
WIPO Patent Application WO/2022/065424
Kind Code:
A1
Abstract:
A carcinostatic agent, a carcinogenesis inhibitor and/or a life-prolonging agent each comprising a compound with mTORC1 inhibitory effect, said compound having partial structures (I), (II) and (III), or a pharmacologically acceptable salt thereof. (In the formulae: R1, R2, R3 and R4 are the same or different and represent an H, a lower alkyl, a lower haloalkyl, a lower alkoxy, a lower alkylamino, an OH, a protected OH, an amino, a protected amino, a carboxy, a protected carboxy or a halogen atom; R5 and R6 are the same or different and represent an H or a protecting group of an OH, or R5 and R6 form together a methylene or dimethylmethylene group; and A represents O or S.)

Inventors:
MIYATAKE HIDEYUKI (JP)
ITO YOSHIHIRO (JP)
SHAMS RAEF SOLIMAN AHMED (JP)
MATSUKAWA AKIHIRO (JP)
Application Number:
PCT/JP2021/035038
Publication Date:
March 31, 2022
Filing Date:
September 24, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
RIKEN (JP)
NAT UNIV CORPORATION OKAYAMA UNIV (JP)
International Classes:
A61K31/517; A61P35/00; A61P43/00
Domestic Patent References:
WO2009023558A12009-02-19
Foreign References:
JP2020519567A2020-07-02
JP2011507910A2011-03-10
Other References:
DATABASE REGISTRY [Online]. US: American Chemical Society [retrieved on 18 October 2021], Retrieved from STN., registry no. 2097920-80-2, 899937-70-3, 899937-50-9, 899937-47-4, 899937-44-1, 899937-41-8, 899937-38-3, 899937-35-0, 899922-42-0, 899922-39-5, 899916-36-0, 899910-80-6, 899910-53-3, 899910-50-0, 899910-47-5, 899910-41-9, 899910-39-5, 899787-90-7, 899921-47-2, 899907-54-1, 892267-23-1
URSULA D. RAMIREZ;ANNA S. NIKONOVA;HANQING LIU;ANNA PECHERSKAYA;SARAH H. LAWRENCE;ILYA G. SEREBRIISKII;YAN ZHOU;MATTHEW K. ROBINSO: "Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 15, no. 1, 28 May 2015 (2015-05-28), LONDON, GB , pages 436, XP021223833, ISSN: 1471-2407, DOI: 10.1186/s12885-015-1415-6
MUTHUKUMAR VIJEY AANANDHI, BHATTACHERJEE DEBOJIT, VIJEY AANANDHI M, SRI RAMYA T, SUJATHA R: "SYNTHESIS,CHARACTERIZATION, ANTI-PROSTATE CANCER DOCKING AND IDENTIFICATION OF TARGET SITE OF VARIOUS MANNICH BASES OF QUINAZOLINONES", 1 January 2013 (2013-01-01), XP055915709, Retrieved from the Internet [retrieved on 20220426]
C. L. DOMINGUEZ, FLOYD D. H., XIAO A., MULLINS G. R., KEFAS B. A., XIN W., YACUR M. N., ABOUNADER R., LEE J. K., WILSON G. M., HAR: "Diacylglycerol Kinase alpha is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers", CANCER DISCOVERY, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 3, no. 7, 1 July 2013 (2013-07-01), US , pages 782 - 797, XP055611381, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-12-0215
HARA, KENTA: "Roles of mTOR in ageing and longevity", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 74, no. 9, 1 January 2016 (2016-01-01), JP , pages 1479 - 1484, XP009535210, ISSN: 0047-1852
Attorney, Agent or Firm:
SIKS & CO. (JP)
Download PDF: